<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04201496</url>
  </required_header>
  <id_info>
    <org_study_id>190017</org_study_id>
    <secondary_id>DP3DK106785</secondary_id>
    <nct_id>NCT04201496</nct_id>
  </id_info>
  <brief_title>SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus</brief_title>
  <acronym>CiQ-SGLT2</acronym>
  <official_title>SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ananda Basu, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tandem Diabetes Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety and efficacy of combining SGLT2&#xD;
      inhibitors with closed loop control (CLC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first five participants will be enrolled in a Pilot Study to use the Basal-IQ with&#xD;
      Empagliflozin 10 mg daily for approximately two weeks. These participants will participate in&#xD;
      an estimated 36-48-hour hotel admission to initiate use of Closed Loop Control. The safety&#xD;
      data from the Pilot Study will be presented to the Data Safety Monitoring Board (DSMB) for&#xD;
      review.&#xD;
&#xD;
      Upon DSMB approval, approximately 40 participants will be randomized 1:1 in a crossover&#xD;
      design. Participants will use empagliflozin 5 mg daily. This main study is a randomized&#xD;
      control trial where approximately 50 participants, aged 18 to less than 65 y.o. at time of&#xD;
      consent, will be in the trial for up to 10 weeks.&#xD;
&#xD;
      With empagliflozin:&#xD;
&#xD;
        -  Control-IQ (CiQ) x 4 weeks (CiQ-EMPA) then Basal-IQ x 2 weeks (BiQ-EMPA)&#xD;
&#xD;
        -  Basal-IQ x 2 weeks (BiQ-EMPA) then CiQ x 4 weeks (CiQ-EMPA)&#xD;
&#xD;
      Without empagliflozin:&#xD;
&#xD;
        -  CiQ x 4 weeks (CiQ-NO EMPA) then Basal-IQ x 2 weeks (BiQ-NO EMPA)&#xD;
&#xD;
        -  Basal-IQ x 2 weeks (BiQ-NO EMPA) then CiQ x 4 weeks (CiQ-NO EMPA)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Actual">September 7, 2021</completion_date>
  <primary_completion_date type="Actual">September 7, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will be first randomized to taking empagliflozin or not taking this drug. Participants will then be randomized to using the Basal-IQ insulin pump first or the Control-IQ insulin pump first. Participants then transition to using the other pump.&#xD;
With empagliflozin:&#xD;
Control-IQ x 4 weeks (CiQ-EMPA) then Basal-IQ x 2 weeks (BiQ-EMPA)&#xD;
Basal-IQ x 2 weeks (BiQ-EMPA) then Control-IQ x 4 weeks (CiQ-EMPA)&#xD;
Without empagliflozin:&#xD;
Control-IQ x 4 weeks (CiQ-NO EMPA) then Basal-IQ x 2 weeks (BiQ-NO EMPA)&#xD;
Basal-IQ x 2 weeks (BiQ-NO EMPA) then Control-IQ x 4 weeks (CiQ-NO EMPA)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CGM-measured time in the target range 70-180mg/dl (TIR) during the day</measure>
    <time_frame>6 weeks</time_frame>
    <description>CGM-measured time in the target range 70-180mg/dl (TIR) during the day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time below 70 mg/dl</measure>
    <time_frame>6 weeks</time_frame>
    <description>Time below 70 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time above 180 mg/dl</measure>
    <time_frame>6 weeks</time_frame>
    <description>Time above 180 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time between 70-140 mg/dl 5 hours post prandial</measure>
    <time_frame>6 weeks</time_frame>
    <description>Time between 70-140 mg/dl 5 hours post prandial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability index HBGI</measure>
    <time_frame>6 weeks</time_frame>
    <description>Glucose variability index HBGI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability index LBGI</measure>
    <time_frame>6 weeks</time_frame>
    <description>Glucose variability index LBGI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability index ADRR</measure>
    <time_frame>6 weeks</time_frame>
    <description>Glucose variability index ADRR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation of empagliflozin as adjuvant therapy added to a closed loop artificial pancreas system</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of episodes of diabetic ketoacidosis (DKA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation of empagliflozin as adjuvant therapy added to a closed loop artificial pancreas system</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of episodes of severe hypoglycemia (glucose &lt;50 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of diabetes ketoacidosis (DKA)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The number of DKA events in the experimental group as compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of severe hypoglycemia (glucose &lt;50 mg/dL)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The number of hypoglycemic events in the experimental group as compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genital infections</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of genital infections (balanitis, urethritis, vulvar infections, Fournier's gangrene) that occur in the experimental group versus the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Tract Infections</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of urinary tract infections that occur in the experimental group versus the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of insulin used</measure>
    <time_frame>6 weeks</time_frame>
    <description>The number of amount of insulin used in the experimental group as compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hyperglycemic episodes as defined by contiguous CGM above 300 mg/dL</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of hyperglycemic episodes, defined as contiguous CGM values above 300 mg/dL, that occur in the experimental group versus the control group</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control-IQ x 4 weeks (CiQ-EMPA) then Basal-IQ x 2 weeks (BiQ-EMPA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin + Basal-IQ x 2 wks then CiQ x 4 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basal-IQ x 2 weeks (BiQ-EMPA) then Control-IQ x 4 weeks (CiQ-EMPA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control-IQ x 4 weeks (CiQ-NO EMPA) then Basal-IQ x 2 weeks (BiQ-NO EMPA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Basal-IQ x 2 weeks (BiQ-NO EMPA) then Control-IQ x 4 weeks (CiQ-NO EMPA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks</intervention_name>
    <description>Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks.</description>
    <arm_group_label>Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks</intervention_name>
    <description>Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks.</description>
    <arm_group_label>Empagliflozin + Basal-IQ x 2 wks then CiQ x 4 wks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks</intervention_name>
    <description>Participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Empaglizflozin will not be provided to this group.</description>
    <arm_group_label>No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks</intervention_name>
    <description>Participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Empaglizflozin will not be provided to this group.</description>
    <arm_group_label>No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18.0 and ≤65 years old at time of consent&#xD;
&#xD;
          2. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least&#xD;
             one year&#xD;
&#xD;
          3. Currently using an insulin pump for at least six months&#xD;
&#xD;
          4. Currently using insulin for at least six months&#xD;
&#xD;
          5. Using insulin parameters such as carbohydrate ratio and correction factors&#xD;
             consistently on their pump in order to dose insulin for meals or corrections&#xD;
&#xD;
          6. Access to internet and willingness to upload data during the study as needed&#xD;
&#xD;
          7. For females, not currently known to be pregnant or breastfeeding&#xD;
&#xD;
          8. If female and sexually active, must agree to use a form of contraception to prevent&#xD;
             pregnancy while a participant in the study. A negative serum or urine pregnancy test&#xD;
             will be required for all females of childbearing potential. Participants who become&#xD;
             pregnant will be discontinued from the study. Also, participants who during the study&#xD;
             develop and express the intention to become pregnant within the timespan of the study&#xD;
             will be discontinued.&#xD;
&#xD;
          9. Willingness to suspend use of any personal CGM for the duration of the clinical trial&#xD;
             once the study CGM is in use&#xD;
&#xD;
         10. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already,&#xD;
             and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the&#xD;
             study&#xD;
&#xD;
         11. Total daily insulin dose (TDD) at least 10 U/day&#xD;
&#xD;
         12. Willingness not to start any new non-insulin glucose-lowering agent during the course&#xD;
             of the trial (including metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors,&#xD;
             biguanides, sulfonylureas and naturaceuticals)&#xD;
&#xD;
         13. Willingness to eat at least 100 grams of carbohydrates per day&#xD;
&#xD;
         14. An understanding and willingness to follow the protocol and signed informed consent&#xD;
&#xD;
         15. Pilot Participants: Agree to hotel/research house admission with other Pilot&#xD;
             participants on a date selected by the study team.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hemoglobin A1c &gt;9%&#xD;
&#xD;
          2. History of diabetic ketoacidosis (DKA) in the 12 months prior to enrollment&#xD;
&#xD;
          3. Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months&#xD;
             prior to enrollment&#xD;
&#xD;
          4. Pregnancy or intent to become pregnant during the trial&#xD;
&#xD;
          5. Currently breastfeeding or planning to breastfeed&#xD;
&#xD;
          6. Currently being treated for a seizure disorder&#xD;
&#xD;
          7. Planned surgery during study duration&#xD;
&#xD;
          8. History of cardiac arrhythmia (except for benign premature atrial contractions and&#xD;
             benign premature ventricular contractions which are permitted)&#xD;
&#xD;
          9. Clinically significant electrocardiogram (ECG) abnormality at time of Screening, as&#xD;
             interpreted by the study medical physician&#xD;
&#xD;
         10. Use of diuretics (e.g. Lasix, Thiazides)&#xD;
&#xD;
         11. History of chronic or recurrent genital infections&#xD;
&#xD;
         12. eGFR lab value below 60 mL/min/1.73 m2&#xD;
&#xD;
         13. Treatment with any non-insulin glucose-lowering agent (including metformin, GLP-1&#xD;
             agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas&#xD;
             and naturaceuticals)&#xD;
&#xD;
         14. A known medical condition that in the judgment of the investigator might interfere&#xD;
             with the completion of the protocol such as the following examples:&#xD;
&#xD;
               1. Severe renal impairment, end-stage renal disease, or dialysis&#xD;
&#xD;
               2. Inpatient psychiatric treatment in the past six months&#xD;
&#xD;
               3. Presence of a known adrenal disorder&#xD;
&#xD;
               4. Abnormal liver function test results (Transaminase&gt;2 times the upper limit of&#xD;
                  normal); testing required for subjects taking medications known to affect liver&#xD;
                  function or with diseases known to affect liver function&#xD;
&#xD;
               5. Uncontrolled thyroid disease&#xD;
&#xD;
         15. Severe renal impairment, end-stage renal disease, or dialysis&#xD;
&#xD;
         16. Use of an automated insulin delivery mechanism that is not downloadable by the subject&#xD;
             or study team&#xD;
&#xD;
         17. Current enrollment in another clinical trial, unless approved by the investigator of&#xD;
             both studies or if clinical trial is a non-interventional registry trial&#xD;
&#xD;
         18. Alcohol restricted to no more than 2 drinks per night in men and no more than 1 drink&#xD;
             per night in women&#xD;
&#xD;
         19. Low carb diet (less than 100g per day)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ananda Basu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralf Nass, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia, Center for Diabetes Technology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Ananda Basu, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Artificial Pancreas (AP)</keyword>
  <keyword>Sodium-glucose co-transporter 2 (SGLT2) inhibitor</keyword>
  <keyword>Insulin Pumps</keyword>
  <keyword>Continuous Glucose Monitor (CGM)</keyword>
  <keyword>Closed Loop Control</keyword>
  <keyword>Low blood glucose index (LBGI)</keyword>
  <keyword>High blood glucose index (HBGI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>To be determined</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>After publication for one year</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

